Received Feb 23, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | — | — |
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 1 | — | — |
the patient referred they received the dose when they were 27 years old, not immunocompromised; the patient referred they received the dose when they were 27 years old, not immunocompromised; This non-serious case was reported by a nurse via call center representative and described the occurrence of inappropriate age at vaccine administration in a 27-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis. Co-suspect products included Herpes zoster (Shingrix) for prophylaxis. On 13-FEB-2026, the patient received the 2nd dose of Shingrix. On an unknown date, the patient received the 1st dose of Shingrix. On 13-FEB-2026, an unknown time after receiving Shingrix and not applicable after receiving Shingrix, the patient experienced inappropriate age at vaccine administration (Verbatim: the patient referred they received the dose when they were 27 years old, not immunocompromised). On an unknown date, the patient experienced inappropriate age at vaccine administration (Verbatim: the patient referred they received the dose when they were 27 years old, not immunocompromised). The outcome of the inappropriate age at vaccine administration and inappropriate age at vaccine administration were not applicable. Additional Information: GSK Receipt Date: 13-FEB-2026 The reporter called to report that they had received a series of Shingrix and did not remember the expiration date, vaccination date, or lot number. The patient stated that they had received the dose when they were 27 years old, were not immunocompromised, and wanted to know whether GlaxoSmithKline had data on administering a booster series. The batch number was not provided upon follow up with the reporter.